# Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)

> **NCT02059681** · PHASE1 · COMPLETED · sponsor: **Centro Cardiologico Monzino** · enrollment: 12 (actual)

## Conditions studied

- Chronic Myocardial Ischemia

## Interventions

- **OTHER:** Autologous bone marrow derived-CD133+ cells

## Key facts

- **NCT ID:** NCT02059681
- **Lead sponsor:** Centro Cardiologico Monzino
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2022-02
- **Final completion:** 2022-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059681, "Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02059681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*